Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 7, 1997, Pages 5-10

  Schatzberg, Alan F ^g   Haddad, Peter ^a   Kaplan, Eric M ^b   Lejoyeux, Michel ^c   Rosenbaum, Jerrold F ^d   Young, A H ^e   Zajecka, John ^f  

^a Prestwich Hospital   (United Kingdom)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BICHAT HOSPITAL   (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY NEUROSIS; DEPRESSION; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; WITHDRAWAL SYNDROME;

DEPRESSIVE DISORDER; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INCIDENCE; NAUSEA; PARESTHESIA; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SLEEP STAGES; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME; TREATMENT REFUSAL;

EID: 0030788305     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology. Int Clin Psychopharmacol 1987;2:1-19
2. Ceccherini-Nelli A, Bordellini L, Guazzalli M, et al. Antidepressant withdrawal phenomena: prospective findings [letter]. Am J Psychiatry 1993;150:165
3. Halle MT, Dilsaver SC. Tranylcypromine withdrawal phenomena. J Psychiatry Neurosci 1993;18:49-50
4. Committee on Safety of Medicines and Medicines Control Agency. Dystonia and withdrawal symptoms with paroxetine (Seroxat). Current Problems in Pharmacovigilance 1993;19:1
5. Adverse Drug Reactions Advisory Committee (ADRAC). SSRIs and withdrawal syndrome. Australian Adverse Drug Reaction Bulletin 1996;15:3
6. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
7. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation [letter]. J Clin Psychopharmacol 1995;15: 374-375
8. Otani K, Tunaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994;9:131-134
9. Montalbetti DJ, Zis AP. Cholinergic rebound following trazodone withdrawal [letter]? J Clin Psychopharmacol 1988;8:73
10. Farah A, Laurer TE. Possible venlafaxine withdrawal syndrome [letter]. Am J Psychiatry 1996;153:576
11. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of 10 cases [letter]. J Clin Psychopharmacol 1996;16:81-84
12. Priest RG, Vize C, Tyke A. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before launch. BMJ 1996;313:858-859
13. Donoghue J, Tylee A, Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996;313:861-862
14. Young AH, Currie A. Physicians' knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiatry 1997;58(suppl 7):28-30
15. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42:757-763
16. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome [letter]? Biol Psychiatry 1993;33:851-852
17. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
18. Einbinder E. Fluoxetine withdrawal [letter]? Am J Psychiatry 1995; 152:1235
19. Baer L, Ricciardi J, Keuthen N, et al. Discontinuing obsessive-compulsive disorder medication with behavior therapy [letter]. Am J Psychiatry 1994;151:1842
20. Bhaumik S, Wildgust HJ. Letter. Human Psychopharmacology 1996; 11:337-338
21. Lader M. Benzodiazepine withdrawal states. In: Trimble MR, ed. Benzodiazepines Divided. New York, NY: John Wiley; 1983:17-31
22. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol 1994;14:206-207
23. Pyke RE. Paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:149-150
24. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54: 146-149
25. Gaikas WJ, Davis SM. Withdrawal from venlafaxine treated with fluoxetine. Psychiatric Annals 1997;27:85-92
26. Pacheco L, Malo P, Aragues E, et al. More cases of paroxetine withdrawal syndrome [letter]. Br J Psychiatry 1996;169:384
27. Bloch M, Stuger SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995;346:57
28. Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors [letter]. Am J Psychiatry 1995;152:810
29. Kasantikul D. Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand 1995;78:53-54
30. Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal [letter]. Am J Psychiatry 1995;152:1235-1236
31. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15:778-780
32. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). Journal of Serotonin Research 1996;3:75-83